Kamuvudine-9 / Inflammasome Therap - LARVOL DELTA

Inflammasome Blockade Prevents Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: Evidence from Murine Allogeneic Transplant Models (TCT-ASTCT-CIBMTR 2026) - "We investigated the involvement of the inflammasome in activating inflammatory pathways, and its inhibitor Kamuvudine-9 (K-9) in the GI aGVHD murine model... The treatment with K-9 resulted in improved epithelial barrier integrity, reduced pro- inflammatory cytokines and cells. The reduced apoptotic cell and proliferative potential suggest inflammasome inhibition and therapeutic potential of K-9 by protecting against GI injury in aGVHD pathophysiology. Subsequent investigations will focus on defining the transcriptional and metabolomic signatures that govern the therapeutic efficacy of K-9 in attenuating aGVHD pathogenesis preclinical research on Graft versus host disease"

Preclinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation • OCLN • TNFA

Therapeutic Targeting of the Inflammasome to Mitigate Murine Sclerodermatous Chronic Graft Versus Host Disease (ASH 2024) - "In this study, we evaluated the efficiency of kamuvudine-9 (K-9), a derivative of nucleoside reverse transcriptase inhibitors, as an inflammasome inhibitor (NLRP3 and NLRC4) to reduce sclerodermatous skin cGVHD...Conclusion : Our results demonstrate that specific inhibition of NLRP3 inflammasome with K-9 has a beneficial role in ameliorating cGVHD of the skin. Future work will focus on molecular transcriptional signatures and metabolomic pathways affected by this novel approach to target cGVHD of the skin to expand not only prevention and therapeutic modalities but also pathophysiologic understanding of this disease."

Preclinical • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dermatopathology • Fibrosis • Graft versus Host Disease • Hematological Malignancies • Immunology • Oncology • Scleroderma • Systemic Sclerosis • CASP8 • NLRP3 • TNFA

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) (clinicaltrials.gov) - P1 | N=13 | Recruiting | Sponsor: Peter Timoney | Trial completion date: May 2025 ➔ Aug 2027 | Trial primary completion date: May 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Ophthalmology • Thyroid Eye Disease

Evaluation of K9 in Subjects with Diabetic Macular Edema (DME) (clinicaltrials.gov) - P1 | N=5 | Recruiting | Sponsor: Michelle Abou-Jaoude | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetic Macular Edema • Ophthalmology

Evaluation of K9 in Subjects with Diabetic Macular Edema (DME) (clinicaltrials.gov) - P1 | N=5 | Not yet recruiting | Sponsor: Michelle Abou-Jaoude

New P1 trial • Diabetic Macular Edema • Ophthalmology

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: Peter Timoney | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology • Thyroid Eye Disease

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Peter Timoney

New P1 trial • Ophthalmology • Thyroid Eye Disease